Sara El‐Sahli

503 total citations
14 papers, 368 citations indexed

About

Sara El‐Sahli is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Sara El‐Sahli has authored 14 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Sara El‐Sahli's work include Cancer Cells and Metastasis (3 papers), Nanoplatforms for cancer theranostics (3 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Sara El‐Sahli is often cited by papers focused on Cancer Cells and Metastasis (3 papers), Nanoplatforms for cancer theranostics (3 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Sara El‐Sahli collaborates with scholars based in Canada, China and United States. Sara El‐Sahli's co-authors include Lisheng Wang, Ying Xie, Sheng Liu, Vanessa M. D’Costa, Andrew Sulaiman, Suresh Gadde, Jessie R. Lavoie, Xuguang Li, Marceline Côté and Tommy Alain and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and Frontiers in Immunology.

In The Last Decade

Sara El‐Sahli

14 papers receiving 365 citations

Peers

Countries citing papers authored by Sara El‐Sahli

Since Specialization

Citations

This map shows the geographic impact of Sara El‐Sahli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara El‐Sahli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara El‐Sahli more than expected).

Fields of papers citing papers by Sara El‐Sahli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara El‐Sahli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara El‐Sahli. The network helps show where Sara El‐Sahli may publish in the future.

Co-authorship network of co-authors of Sara El‐Sahli

This figure shows the co-authorship network connecting the top 25 collaborators of Sara El‐Sahli. A scholar is included among the top collaborators of Sara El‐Sahli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara El‐Sahli. Sara El‐Sahli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Nanoparticle-Mediated mRNA Delivery to Triple-Negative Breast Cancer (TNBC) Patient-Derived Xenograft (PDX) Tumors 2025 ·ACS Pharmacology & Translational Science ·Sara El‐Sahli, (unknown), (unknown), Yuxia Bo, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Seung‐Hwan Lee, Umar Iqbal, Marceline Côté, Lisheng Wang, Suresh Gadde	2
2	Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model 2024 ·Frontiers in Immunology ·(unknown), Sara El‐Sahli, Marie Marotel, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Andrew Sulaiman, (unknown), Jessie R. Lavoie, Zhen Liu, Seung‐Hwan Lee, Xuguang Li, Giuseppe Sciumè, Vanessa M. D’Costa, Michele Ardolino, Lisheng Wang	7
3	Nanoparticles Codelivering mRNA and SiRNA for Simultaneous Restoration and Silencing of Gene/Protein Expression In Vitro and In Vivo 2024 ·SHILAP Revista de lepidopterología ·(unknown), Sara El‐Sahli, Yuxia Bo, (unknown), (unknown), (unknown), (unknown), (unknown), Seunghwan Lee, Umar Iqbal, Marceline Côté, (unknown), Suresh Gadde	6
4	Analysis of financial challenges faced by graduate students in Canada 2023 ·Biochemistry and Cell Biology ·(unknown), Thomas J. Bailey, (unknown), (unknown), (unknown), Matthew D. Berg, (unknown), (unknown), (unknown), Sara El‐Sahli, Dominique Boucher, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	5
5	Applications of Extracellular Vesicles in Triple-Negative Breast Cancer 2022 ·Cancers ·(unknown), (unknown), (unknown), Sara El‐Sahli, (unknown), Jessie R. Lavoie	26
6	A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature 2021 ·Cell Death and Disease ·Sara El‐Sahli, (unknown), Andrew Sulaiman, (unknown), Li Li, (unknown), (unknown), Dan Liu, Peiyong Zheng, Seung Hwan Lee, Jiefeng Cui, Marc Ekker, Marceline Côté, Tommy Alain, Xuguang Li, Vanessa M. D’Costa, Lisheng Wang, Suresh Gadde	35
7	The Potential of Natural Products in the Treatment of Triple-negative Breast Cancer 2021 ·Current Cancer Drug Targets ·(unknown), Sara El‐Sahli, Lisheng Wang	23
8	Nanoparticles Loaded with Wnt and YAP/Mevalonate Inhibitors in Combination with Paclitaxel Stop the Growth of TNBC Patient‐Derived Xenografts and Diminish Tumorigenesis 2020 ·Advanced Therapeutics ·Andrew Sulaiman, (unknown), Sara El‐Sahli, Li Li, (unknown), (unknown), (unknown), (unknown), (unknown), Guang Ji, Seunghwan Lee, Krishna Kishore Inampudi, Tommy Alain, Xuguang Li, Sheng Liu, Xianghui Han, Peiyong Zheng, Zhen Liu, Suresh Gadde, Lisheng Wang	4
9	Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer 2020 ·Cancers ·(unknown), Sara El‐Sahli, Vanessa M. D’Costa, (unknown)	74
10	Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer 2020 ·International Journal of Molecular Sciences ·Sara El‐Sahli, (unknown)	33
11	Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy 2019 ·Molecular Cancer Therapeutics ·Andrew Sulaiman, (unknown), Sara El‐Sahli, Li Li, (unknown), (unknown), Marceline Côté, Greg O. Cron, Tommy Alain, Yevgeniya Le, Seung‐Hwan Lee, Sheng Liu, Daniel Figeys, Suresh Gadde, Lisheng Wang	21
12	Abstract 2998: Co-targeting bulk tumor and CSCs in clinically translatable TNBC patient-derived xenografts via combination nanotherapy 2019 ·(unknown), Sara El‐Sahli, (unknown), Lisheng Wang, Suresh Gadde	1
13	Wnt Signaling in Cancer Metabolism and Immunity 2019 ·Cancers ·Sara El‐Sahli, Ying Xie, Lisheng Wang, Sheng Liu	94
14	Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells 2018 ·Cell Death and Disease ·Andrew Sulaiman, (unknown), (unknown), Sara El‐Sahli, (unknown), (unknown), Li Li, Christina Addison, Jim Dimitroulakos, Angel Arnaout, Carolyn Nessim, Zemin Yao, Guang Ji, Haiyan Song, Sheng Liu, Ying Xie, Suresh Gadde, Xuguang Li, Lisheng Wang	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact